Ardian’s Riemser bolts on Intrapharm

Riemser stated that the acquisition of Intrapharm would strengthen its product offering in the UK and expand the company's access to the Nordic and Irish markets.

Riemser does not plan changes to Intrapharm's management team.

Previous funding
Ardian acquired its majority stake in Riemser Arzneimittel in August 2012 from the company's founding family and minority investors, including TVM Capital.

In December 2007, TVM invested €18m for a 10% stake in Riemser. The firm helped the company internationalise, particularly in Asia, western Europe and the Americas.

Intrapharm received a £2m investment from Business Growth Fund in August 2014, to facilitate the acquisition of Peckforton Pharmaceuticals.

Company
Founded in 1999 and based in Maidenhead, Intrapharm markets speciality pharmaceutical products, focusing on prescription-based and selected over-the-counter products.

People
Konstantin von Alvensleben is CEO of Riemser. Kevin James is director of Intrapharm's UK business. Christof Naményi is managing director and Matthias Breuckmann is senior investment manager at Ardian.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• UK / Ireland
• Healthcare
• Buyouts
• Germany
• United Kingdom
• Ardian (formerly Axa PE)